Jami Rubin is Director at Relay Therapeutics, Inc. (RLAY). They have made 1 open-market trade across 1 company since 2020, most recently 2024-06-10.
CIK 0001816484
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $500K since 2020, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RLAY | BUY | 2020-07-20 | 2020-07-21 | $20.00 | $500K | -12.1% | -8.4% | +1.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.